ישראל - עברית - Ministry of Health

bayer israel ltd - drospirenone; ethinylestradiol - טבליות מצופות פילם - drospirenone 3 mg; ethinylestradiol 0.02 mg - drospirenone and estrogen - drospirenone and estrogen - - oral contraception. - treatment of moderate acne vulgaris in women who seek oral contraception. - treatment of symptoms of premenstrual dysphoric disorder (pmdd ) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms ( premenstrual syndrome ).

ישראל - עברית - Ministry of Health

bayer israel ltd - ethinylestradiol; gestodene - טבליות מצופות - ethinylestradiol 0.03 mg; gestodene 0.075 mg - ethinylestradiol - ethinylestradiol - hormonal contraception.

ישראל - עברית - Ministry of Health

bayer israel ltd - dienogest; dienogest; estradiol valerate; estradiol valerate; estradiol valerate - טבליות מצופות פילם - estradiol valerate 1 mg; estradiol valerate 3 mg; dienogest 2 mg; dienogest 3 mg; estradiol valerate 2 mg - estradiol - estradiol - oral contraception.treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception.

ישראל - עברית - Ministry of Health

bayer israel ltd - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 35 mcg; cyproterone acetate 2 mg - cyproterone and estrogen - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.

ישראל - עברית - Ministry of Health

bayer israel ltd - cyproterone acetate; ethinylestradiol - טבליה - ethinylestradiol 35 mcg; cyproterone acetate 2 mg - cyproterone and estrogen - cyproterone and estrogen - treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. for the treatment of acne, diane-35 should only be used after topical therapy or systemic antibiotic treatments have failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

ישראל - עברית - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.

ישראל - עברית - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.